Lin Zhang

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

R. Eastell, J. S. San Martin, S. Ralston, 2019, Calcified Tissue International.

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis

J. S. San Martin, R. Lachmann, H. Cheong, 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial

J. S. San Martin, F. Rauch, T. Kubota, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

R. Eastell, J. S. San Martin, S. Ralston, 2019, Calcified Tissue International.

A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)

R. Eastell, S. Ralston, M. Brandi, 2018 .